JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: CA-327 is a novel potent, orally available, small molecule and dual inhibitor of TIM3 and PD-L1 with potential anticancer activities. In addition to PD-1, there are several other checkpoints involved in the modulation of immune responses to tumor cells. One such checkpoint is T-cell immunoglobulin and mucin domain containing protein-3 (TIM3), which shares some structural similarity with PD-L1. TIM3 is also a potent suppressor of T cell functions and is co-expressed with programmed cell death-1 (PD-1) receptors on certain T cells. TIM3 modulates immune response by binding to one or more of its ligands: galectin 9 (GAL9), phosphatidyl serine, high mobility group protein B1 (HMGB1) and Ceacam-1. Animal studies have demonstrated that combined inhibition of PD-L1 and TIM3 results in improved anti-tumor responses in certain tumor models, highlighting their independent roles in regulating immune response to tumors.
References: http://www.curis.com/pipeline/ca-327
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Recommend by mail
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!